Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Bruton tyrosine kinase inhibitor
Waldenström macroglobulinaemia
treatment
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
10
06
2022
accepted:
19
11
2022
medline:
17
5
2023
pubmed:
29
11
2022
entrez:
28
11
2022
Statut:
ppublish
Résumé
Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with plasmacytic differentiation and the MYD88 L265P mutation in >90% of cases. Traditionally, WM has been treated with chemoimmunotherapy. Recent trials have demonstrated the efficacy and safety of Bruton tyrosine kinase inhibitors in WM, both as monotherapy and in combination with other drugs. There is emerging evidence on the use of other agents including B-cell lymphoma 2 inhibitors and on the treatment of rare presentations of WM. In this update, the Medical and Scientific Advisory Group of Myeloma Australia reviews the available evidence on the treatment of WM since the last publication in 2017 and provides specific recommendations to assist Australian clinicians in the management of this disease.
Substances chimiques
Antineoplastic Agents
0
Myeloid Differentiation Factor 88
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-609Informations de copyright
© 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Swerdlow SHCE, Harris NL, Jaffe ES, Plieri SA, Stein H, Thiele J. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC; 2017.
Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H et al. Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J 2017; 47: 35-49.
Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Group, A, et al. Consensus clinical practice guidelines for the treatment of patients with Waldenström Macroglobulinaemia; 7 June 2022. Available from URL: https://myeloma.org.au/wp-content/uploads/2022/06/MSAG_waldenstro%CC%88m-guidelines_jun22.pdf
Maqbool MG, Tam CS, Morison IM, Simpson D, Mollee P, Schneider H et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology 2020; 52: 167-78.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-10.
Rummel MJ, Lerchenmüller C, Greil R, Goerner M, Hensel M, Engel E, et al. Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenström's macroglobulinemia: results from a prospective, randomized, multicenter study (StiL NHL 7-2008 -MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). ASH abstract 2012 (abstract).
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 2016; 17: 57-66.
Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25: 3344-9.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 2015; 372: 1430-40 (In eng).
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia. N Engl J Med 2018; 378: 2399-410.
Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017; 18: 241-50.
Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G et al. Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up. Blood 2020; 136: 2027-37.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood 2020; 136: 2038-50.
Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 2020; 4: 6009-18.
Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S et al. Consensus statement on the management of Waldenstrom macroglobulinemia patients during the COVID-19 pandemic. Hemasphere 2020; 4: e433.
Buske C, Dreyling M, Alvarez-Larran A, Apperley J, Arcaini L, Besson C et al. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 2022; 7: 100403.
Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 2017; 102: 43-51.
Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood 2019; 133: 299-305.
Talaulikar D, Biscoe A, Lim JH, Gibson J, Arthur C, Mackinlay N et al. Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstrom Macroglobulinaemia reveals different patterns of clonal evolution. Br J Haematol 2019; 185: 767-70.
Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012; 119: 4462-6.
Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia. Lancet Haematol 2020; 7: e827-37.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S et al. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw 2012; 10: 1211-9 (In eng).